Clear Search sequence regions


Sizes of these terms reflect their relevance to your search.

Up-regulating programmed cell death ligand-1(PD-L1) expressed on tumor cells and tumor-infiltrating myeloid cells interacting with up-regulated programmed cell death-1 (PD-1) expressed on tumor-infiltrating lymphoid cells greatly hinder their tumor-inhibiting effect. It is necessary to explore the deep mechanism of this negative effect, so as to find the potential methods to improve the immunotherapy efficiency. In this study, we found that the PD-1 expression in lung cancer-infiltrating type II innate lymphoid cells (ILC2s) was highly up-regulated, which greatly restrained the activation and function of ILC2s. Furthermore, anti-PD-1 could restore the inhibition and effective cytokine secretion of ILC2s when co-cultured with tumor cells. In vivo studies proved that anti-PD-1 treatment promoted the activation of tumor-infiltrating ILC2s and inhibited the tumor growth of LLC-bearing nude mice. Our studies demonstrate a new PD-1/PD-L1 axis regulating mechanism on innate immune cells, which provide a useful direction to ILC2s-based immunotherapy to cancer diseases.

Citation

Chaoyun Yin, Yani Pa, Guangyu Li, Qiang Chen, Xizu Wang, Xijun He, Huangao Zhou. Tumor cells inhibit the activation of ILC2s through up-regulating PD-1 expression. Immunopharmacology and immunotoxicology. 2024 Jun;46(3):417-423

Expand section icon Mesh Tags

Expand section icon Substances


PMID: 38678437

View Full Text